JP2024540083A5 - - Google Patents
Info
- Publication number
- JP2024540083A5 JP2024540083A5 JP2024525338A JP2024525338A JP2024540083A5 JP 2024540083 A5 JP2024540083 A5 JP 2024540083A5 JP 2024525338 A JP2024525338 A JP 2024525338A JP 2024525338 A JP2024525338 A JP 2024525338A JP 2024540083 A5 JP2024540083 A5 JP 2024540083A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cancer
- antigen
- sequences
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272374P | 2021-10-27 | 2021-10-27 | |
| US63/272,374 | 2021-10-27 | ||
| PCT/US2022/078780 WO2023076998A1 (en) | 2021-10-27 | 2022-10-27 | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540083A JP2024540083A (ja) | 2024-10-31 |
| JP2024540083A5 true JP2024540083A5 (https=) | 2025-08-28 |
Family
ID=86158721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525338A Pending JP2024540083A (ja) | 2021-10-27 | 2022-10-27 | 抗ＮＲＰ２ａ抗体を含む組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240417476A1 (https=) |
| EP (1) | EP4423142A4 (https=) |
| JP (1) | JP2024540083A (https=) |
| CN (1) | CN118355033A (https=) |
| AU (1) | AU2022375785A1 (https=) |
| CA (1) | CA3234409A1 (https=) |
| WO (1) | WO2023076998A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019247511B2 (en) | 2018-04-06 | 2025-10-16 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| CA3156803A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| TWI541021B (zh) * | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Ｉｌ－１７結合蛋白 |
| CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| WO2012144208A1 (ja) * | 2011-04-18 | 2012-10-26 | 国立大学法人東京大学 | 抗itm2a抗体を用いる癌の診断および治療 |
| CA2896058A1 (en) * | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| KR20160131082A (ko) * | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg1-3에 특이적인 항-라미닌4 항체 |
| EP3464349A4 (en) * | 2016-05-23 | 2020-08-26 | New York University | COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS |
| KR102758204B1 (ko) * | 2017-10-30 | 2025-01-23 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 표적 세포의 선택적 형질도입을 위한 어댑터-기반 레트로바이러스 벡터 시스템 |
| AU2019247511B2 (en) * | 2018-04-06 | 2025-10-16 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| KR20210148216A (ko) * | 2019-04-01 | 2021-12-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-클라우딘 18.2 항체 및 이의 응용 |
| WO2021058548A1 (en) * | 2019-09-23 | 2021-04-01 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | Antibodies for the diagnosis and/or treatment of atherosclerosis |
| CA3156803A1 (en) * | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| CN116075525A (zh) * | 2020-03-31 | 2023-05-05 | 艾莱克特有限责任公司 | 抗mertk抗体及其使用方法 |
-
2022
- 2022-10-27 EP EP22888492.0A patent/EP4423142A4/en active Pending
- 2022-10-27 AU AU2022375785A patent/AU2022375785A1/en active Pending
- 2022-10-27 US US18/703,912 patent/US20240417476A1/en active Pending
- 2022-10-27 CN CN202280080506.0A patent/CN118355033A/zh active Pending
- 2022-10-27 JP JP2024525338A patent/JP2024540083A/ja active Pending
- 2022-10-27 CA CA3234409A patent/CA3234409A1/en active Pending
- 2022-10-27 WO PCT/US2022/078780 patent/WO2023076998A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379561B2 (ja) | キメラ抗原及びｔ細胞受容体、並びに使用方法 | |
| JP2021521110A5 (https=) | ||
| CN109843921B (zh) | 程序性死亡1配体1(pd-l1)结合蛋白及其应用方法 | |
| JP7295795B2 (ja) | 免疫調節ポリペプチドならびに関連する組成物および方法 | |
| JP2022551603A5 (https=) | ||
| US20190048085A1 (en) | Modified cells for immunotherapy | |
| JP2020015753A (ja) | Ｐｄ１および／またはｌａｇ３結合性物質 | |
| JP2021531313A5 (https=) | ||
| JP2017511687A5 (https=) | ||
| AU2016212161A1 (en) | CLL1-specific multi-chain chimeric antigen receptor | |
| JP2017516489A5 (https=) | ||
| JP2020525005A5 (https=) | ||
| JP2024540083A5 (https=) | ||
| CN113906049A (zh) | 用于共施用针对c-kit和CD47的免疫治疗剂的方案 | |
| WO2021027785A1 (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| CN117586416A (zh) | 双特异性嵌合抗原受体和免疫细胞、制备方法、应用及肿瘤治疗药品 | |
| EP4261277A2 (en) | Methods of treating cancer and infectious diseases using cell based therapies | |
| EP4182337B1 (en) | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods | |
| CN118126194A (zh) | 靶向cd70的嵌合抗原受体 | |
| CN110004167A (zh) | 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用 | |
| WO2021115333A1 (zh) | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 | |
| Vlaming | Novel T cell biomarkers and the development of immunotherapeutic anti-tumor strategies | |
| AU2024370365A1 (en) | Cd40-targetting antibodies and uses thereof | |
| HK40068212A (en) | Regimes for co-administration of immunotherapeutic agents against c-kit and cd47 | |
| CN113528560A (zh) | 靶向白蛋白的嵌合抗原受体及其使用方法 |